How Tysabri survived.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 19898447.
- Also identified by DOI 10.1038/nbt1109-986.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Most drugs withdrawn from the market because of serious toxicities never make it back. But Biogen Idec succeeded in getting its multiple sclerosis (MS) drug Tysabri reintroduced in less than 16 months.
Medical subject headings
- Antibodies, Monoclonal